Pathological findings in central nervous system demyelination associated with infliximab

Alicja Kalinowska-Lyszczarz, Mahboobeh Fereidan-Esfahani, Yong Guo, Claudia F. Lucchinetti, W. Oliver Tobin

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.

Original languageEnglish (US)
Pages (from-to)1124-1129
Number of pages6
JournalMultiple Sclerosis Journal
Issue number9
StatePublished - Aug 1 2020


  • Demyelination
  • central nervous system
  • infliximab
  • multiple sclerosis
  • neuropathology
  • rheumatoid arthritis
  • tumor necrosis factor (TNF) alpha inhibitors

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Pathological findings in central nervous system demyelination associated with infliximab'. Together they form a unique fingerprint.

Cite this